Evidence map›Paper›PMID 41048130›Full record

ArticleCancer science2025

Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report.

Maako Kawamura, Hiroshi Tada, Hidekazu Shirota, Miki Dobashi, Noriko Takenaga, Hiroyuki Yasojima, Narumi Harada-Shoji, Keigo Komine, Kenichi Nakamura, Minoru Miyashita and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maako KawamuraPersonalized Medicine Center, Tohoku University Hospital, Sendai, Japan.
Hiroshi TadaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Hospital, Sendai, Japan.
Hidekazu ShirotaDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0001-9154-9004
Miki DobashiPersonalized Medicine Center, Tohoku University Hospital, Sendai, Japan.
Noriko TakenagaPersonalized Medicine Center, Tohoku University Hospital, Sendai, Japan.
Hiroyuki YasojimaClinical Genetics Center, NHO Osaka National Hospital, Osaka, Japan.
Narumi Harada-ShojiDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0002-7001-0541
Keigo KomineDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Kenichi NakamuraClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3534-8296
Minoru MiyashitaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0002-4151-8725
Hisato KawakamiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.

Funding

National Cancer CenterTakeda Pharmaceutical Company
6 · The paper itself

Abstract

This case study describes the clinical course of a 39-year-old woman with metastatic breast cancer harboring a germline PALB2 mutation who was treated with a PARP inhibitor. She initially demonstrated a clinical benefit with reduced tumor markers and favorable imaging findings. However, disease progression occurred after eight months. Liquid biopsy-based genomic profiling identified three PALB2 reversion mutations that restored homologous recombination, leading to treatment resistance. The case illustrates both the therapeutic potential of PARP inhibitors in PALB2-mutated cancers and the emergence of resistance. It emphasizes the importance of liquid biopsy-based genomic profiling for understanding tumor evolution and guiding treatment strategies.

Indexed as

AminopyridinesBreast NeoplasmsDrug Resistance, NeoplasmFanconi Anemia Complementation Group N ProteinIndazolesPiperidinesPoly(ADP-ribose) Polymerase InhibitorsAdultFemaleGerm-Line MutationHumansLiquid BiopsyAminopyridinesFanconi Anemia Complementation Group N ProteinIndazolesniraparibPALB2 protein, humanPiperidinesPoly(ADP-ribose) Polymerase Inhibitorsbreast cancerCGP testPALB2PARP inhibitorreversion mutation

Identifiers

PMID41048130
PMCPMC12666475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.